Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Cash from Investing Activities (2020 - 2025)

Lyell Immunopharma's Cash from Investing Activities history spans 6 years, with the latest figure at $3.3 million for Q3 2025.

  • For Q3 2025, Cash from Investing Activities rose 74.61% year-over-year to $3.3 million; the TTM value through Sep 2025 reached $139.0 million, up 537.4%, while the annual FY2024 figure was $122.4 million, 33.48% down from the prior year.
  • Cash from Investing Activities for Q3 2025 was $3.3 million at Lyell Immunopharma, down from $12.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $152.9 million in Q2 2023 and bottomed at -$144.9 million in Q3 2021.
  • The 5-year median for Cash from Investing Activities is $22.0 million (2024), against an average of $13.6 million.
  • The largest annual shift saw Cash from Investing Activities tumbled 328.06% in 2021 before it skyrocketed 511.18% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$73.9 million in 2021, then skyrocketed by 163.16% to $46.6 million in 2022, then crashed by 315.85% to -$100.7 million in 2023, then surged by 153.14% to $53.5 million in 2024, then tumbled by 93.74% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Cash from Investing Activities are $3.3 million (Q3 2025), $12.6 million (Q2 2025), and $69.5 million (Q1 2025).